Literature DB >> 10979977

Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5.

V Sexl1, R Piekorz, R Moriggl, J Rohrer, M P Brown, K D Bunting, K Rothammer, M F Roussel, J N Ihle.   

Abstract

The cytokines interleukin 7 (IL-7) and interleukin 4 (IL-4) regulate lymphoid differentiation and function and activate the transcription factor Stat5. Using mice deficient for the 2 highly related transcription factors, Stat5a and Stat5b (Stat5a/b(-/-)), we investigated the role of Stat5 for B-cell differentiation, expansion, and function. Peripheral blood B cells of Stat5-deficient mice are significantly reduced, but no proliferation defects in response to various mitogenic stimuli are found. Also, IgM and IgG1 antibody production and immunoglobulin class switching are not affected. Pre- and pro-B cells of Stat5-deficient animals were found to have reduced responses to IL-7. Pro- and pre-B cells are the target cells of the abl oncogene and numerous studies have suggested that Stat5a/b is essential for transformation by derivatives of the Abelson (abl) gene. To assess the role of Stat5a/b in transformation, we have evaluated the ability of various abl derivatives to transform cells from Stat5a/b-deficient mice in vitro or in vivo. We demonstrate that the absence of Stat5a/b is not essential for the induction of lymphoid or myeloid tumors in vivo or on the ability to transform bone marrow cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979977

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

Review 1.  Stat proteins and oncogenesis.

Authors:  Jacqueline Bromberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  A developmentally controlled competitive STAT5-PU.1 DNA binding mechanism regulates activity of the Ig κ E3' enhancer.

Authors:  Suchita Hodawadekar; Kyoungsook Park; Michael A Farrar; Michael L Atchison
Journal:  J Immunol       Date:  2012-01-25       Impact factor: 5.422

Review 3.  Research using Mesenchymal Stem/Stromal Cells: quality metric towards developing a reference material.

Authors:  Vivek Tanavde; Candida Vaz; Mahendra S Rao; Mohan C Vemuri; Radhika R Pochampally
Journal:  Cytotherapy       Date:  2015-09       Impact factor: 5.414

4.  Cutting edge: inherent and acquired resistance to radiation-induced apoptosis in B cells: a pivotal role for STAT3.

Authors:  Dennis C Otero; Valeria Poli; Michael David; Robert C Rickert
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

Review 5.  Following the cytokine signaling pathway to leukemogenesis: a chronology.

Authors:  Kendall A Smith; James D Griffin
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

6.  Stat5a/b are essential for normal lymphoid development and differentiation.

Authors:  Zhengju Yao; Yongzhi Cui; Wendy T Watford; Jay H Bream; Kunihiro Yamaoka; Bruce D Hissong; Denise Li; Scott K Durum; Qiong Jiang; Avinash Bhandoola; Lothar Hennighausen; John J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

Review 7.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

8.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 9.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

Review 10.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.